Related references
Note: Only part of the references are listed.Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5
Hamid Salimi et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2013)
Affinofile profiling: How efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV
Kelechi Chikere et al.
VIROLOGY (2013)
Differential Use of CCR5 by HIV-1 Clinical Isolates Resistant to Small-Molecule CCR5 Antagonists
Timothy J. Henrich et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
HIV-1 Clinical Isolates Resistant to CCR5 Antagonists Exhibit Delayed Entry Kinetics That Are Corrected in the Presence of Drug
Opass Putcharoen et al.
JOURNAL OF VIROLOGY (2012)
Enhanced Recognition and Neutralization of HIV-1 by Antibody-Derived CCR5-Mimetic Peptide Variants
Jessica J. Chiang et al.
JOURNAL OF VIROLOGY (2012)
V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc
Reem Berro et al.
VIROLOGY (2012)
Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance
Cleo G. Anastassopoulou et al.
VIROLOGY (2012)
Tyrosine Sulfation Influences the Chemokine Binding Selectivity of Peptides Derived from Chemokine Receptor CCR3
John Z. Zhu et al.
BIOCHEMISTRY (2011)
Divergent and Site-Selective Solid-Phase Synthesis of Sulfopeptides
Deni Taleski et al.
CHEMISTRY-AN ASIAN JOURNAL (2011)
Mapping and Characterization of Vicriviroc Resistance Mutations From HIV-1 Isolated from Treatment-Experienced Subjects Enrolled in a Phase II Study (VICTOR-E1)
Paul M. McNicholas et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2011)
A Tyrosine-Sulfated CCR5-Mimetic Peptide Promotes Conformational Transitions in the HIV-1 Envelope Glycoprotein
Jo Ann Kwong et al.
JOURNAL OF VIROLOGY (2011)
HIV-1 Escape from the CCR5 Antagonist Maraviroc Associated with an Altered and Less-Efficient Mechanism of gp120-CCR5 Engagement That Attenuates Macrophage Tropism
Michael Roche et al.
JOURNAL OF VIROLOGY (2011)
Alternative Coreceptor Requirements for Efficient CCR5-and CXCR4-Mediated HIV-1 Entry into Macrophages
Kieran Cashin et al.
JOURNAL OF VIROLOGY (2011)
HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry
Michael Roche et al.
RETROVIROLOGY (2011)
CD4-binding site alterations in CCR5-using HIV-1 envelopes influencing gp120-CD4 interactions and fusogenicity
Jasminka Sterjovski et al.
VIROLOGY (2011)
Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41
Cleo G. Anastasopoulou et al.
VIROLOGY (2011)
Shift in phenotypic susceptibility suggests a competition mechanism in a case of acquired resistance to maraviroc
Pierre Delobel et al.
AIDS (2010)
HIV Type 1 from a Patient with Baseline Resistance to CCR5 Antagonists Uses Drug-Bound Receptor for Entry
John C. Tilton et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2010)
Evolution of CCR5 Antagonist Resistance in an HIV-1 Subtype C Clinical Isolate
Timothy J. Henrich et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-Tropic HIV-1 Infection
David A. Cooper et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Characterization of Emergent HIV Resistance in Treatment-Naive Subjects Enrolled in a Vicriviroc Phase 2 Trial
Paul McNicholas et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
A Maraviroc-Resistant HIV-1 with Narrow Cross-Resistance to Other CCR5 Antagonists Depends on both N-Terminal and Extracellular Loop Domains of Drug-Bound CCR5
John C. Tilton et al.
JOURNAL OF VIROLOGY (2010)
HIV-1 Resistance to CCR5 Antagonists Associated with Highly Efficient Use of CCR5 and Altered Tropism on Primary CD4+ T Cells
Jennifer M. Pfaff et al.
JOURNAL OF VIROLOGY (2010)
Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5
Robert A. Ogert et al.
VIROLOGY (2010)
An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes
Jasminka Sterjovski et al.
VIROLOGY (2010)
Coreceptors and HIV-1 Pathogenesis
Paul R. Gorry et al.
Current HIV/AIDS Reports (2010)
Virologic Failure in First-Line Human Immunodeficiency Virus Therapy with a CCR5 Entry Inhibitor, Aplaviroc, plus a Fixed-Dose Combination of Lamivudine-Zidovudine: Nucleoside Reverse Transcriptase Inhibitor Resistance Regardless of Envelope Tropism
James F. Demarest et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Virologic Failure in Therapy-Naive Subjects on Aplaviroc plus Lopinavir-Ritonavir: Detection of Aplaviroc Resistance Requires Clonal Analysis of Envelope
Kathryn M. Kitrinos et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Regulation of Chemokine Recognition by Site-Specific Tyrosine Sulfation of Receptor Peptides
Levi S. Simpson et al.
CHEMISTRY & BIOLOGY (2009)
Tissue-Specific Sequence Alterations in the Human Immunodeficiency Virus Type 1 Envelope Favoring CCR5 Usage Contribute to Persistence of Dual-Tropic Virus in the Brain
Lachlan Gray et al.
JOURNAL OF VIROLOGY (2009)
Structure-Function Analysis of Human Immunodeficiency Virus Type 1 gp120 Amino Acid Mutations Associated with Resistance to the CCR5 Coreceptor Antagonist Vicriviroc
Robert A. Ogert et al.
JOURNAL OF VIROLOGY (2009)
A Quantitative Affinity-Profiling System That Reveals Distinct CD4/CCR5 Usage Patterns among Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus Strains
Samantha H. Johnston et al.
JOURNAL OF VIROLOGY (2009)
Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist Therapy In Vivo
Athe M. N. Tsibris et al.
PLOS ONE (2009)
Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41
Cleo G. Anastassopoulou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities
Pavel Pugach et al.
VIROLOGY (2009)
Two HIV-1 Variants Resistant to Small Molecule CCR5 Inhibitors Differ in How They Use CCR5 for Entry
Reem Berro et al.
PLOS PATHOGENS (2009)
Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection
Raphael J. Landovitz et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject
Athe M. N. Tsibris et al.
JOURNAL OF VIROLOGY (2008)
Subgroup analyses of Maraviroc in previously treated R5 HIV-1 infection
Gerd Faetkenheuer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120
Robert A. Ogert et al.
VIROLOGY (2008)
Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS
Jasminka Sterjovski et al.
RETROVIROLOGY (2007)
Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4
Chih-chin Huang et al.
SCIENCE (2007)
V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies
Meg M. Laakso et al.
PLOS PATHOGENS (2007)
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment experienced patients: AIDS clinical trials group 5211
Roy M. Gulick et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry
Pavel Pugach et al.
VIROLOGY (2007)
Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry
Mike Westby et al.
JOURNAL OF VIROLOGY (2007)
Interaction of small molecule inhibitors of HIV-1 entry with CCR5
Christoph Seibert et al.
VIROLOGY (2006)
Structural and molecular interactions of CCR5 inhibitors with CCR5
K Maeda et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Emergence of CXCR4-Using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-Infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir
M Westby et al.
JOURNAL OF VIROLOGY (2006)
Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1
JM Strizki et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Structure of a V3-containing HIV-1 gp120 core
CC Huang et al.
SCIENCE (2005)
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
P Dorr et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Generation and properties of a human immunodeficiency virus type I isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D)
AJ Marozsan et al.
VIROLOGY (2005)
The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor
C Watson et al.
MOLECULAR PHARMACOLOGY (2005)
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor
SE Kuhmann et al.
JOURNAL OF VIROLOGY (2004)
Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-Chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro
K Maeda et al.
JOURNAL OF VIROLOGY (2004)
Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry
F Tsamis et al.
JOURNAL OF VIROLOGY (2003)
Tyrosine-sulfated peptides functionally reconstitute a CCR5 variant lacking a critical amino-terminal region
M Farzan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor
EG Cormier et al.
JOURNAL OF VIROLOGY (2002)
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use
A Trkola et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers
XZ Yang et al.
JOURNAL OF VIROLOGY (2001)
Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120
EG Cormier et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
T Dragic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo
B Etemad-Moghadam et al.
JOURNAL OF VIROLOGY (2000)
Share Paper
